8-K filing — Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and

Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Partner Refiles Tabelecleucel Biologics License Application With FDA

Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 268.42 percent decrease over earnings of $0.19 per share from the same period last